Provista to Present Poster on Serum-Based Diagnostic for Breast Cancer

Provista to Present Poster on Serum-Based Diagnostic for Breast Cancer

Molecular diagnostics company, Provista Diagnostics, Inc., recently announced their acceptance to present a poster at the upcoming San Antonio Breast Cancer Symposium, scheduled Tuesday, December 9 to Saturday, December 13, 2014. The poster, entitled, "Provista-001: a multi-center prospective study of protein signature used in the differentiation of benign breast lesions from invasive breast cancer in women under the age of 50 with a BI-RADS 3 or 4," highlights the company's commitment to develop new and better blood-based diagnostics, prognostics and monitoring tests for women's cancers. The poster will be available for viewing during the conference's Detection and Diagnosis Poster session.

 The American Cancer Society predicts that by the end of 2014, almost 233,000 women will be diagnosed with breast cancer. Every year, 40,000 women die of beast cancer - most of which could have had a better outcome if they had received an earlier, accurate diagnosis and immediately started appropriate treatment. "We are very excited to be accepted
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.